Greystone Associates Analysis
Reveals Growing Interest and Development Activity
(Amherst, NH) – The challenges of delivering drugs to the central
nervous system are well-documented. But, drug developers and
researchers have discovered that delivering CNS therapeutic drugs
via inhalation mitigates several of these issues. The accessibility
and vascular structure of the nose make it an attractive route for
delivering both small molecule drugs and biologics across the
blood-brain barrier to the CNS. Pulmonary delivery to the deep lung
can have favorable pharmacokinetics. And inhaled delivery offers the
potential for faster onset of action and less frequent dosing
relative to oral drugs.
These potential advantages have
spurred activity in inhaled CNS therapeutics for a range of
disorders. As aging population demographics and managed care
initiatives drive growth in home health care and self-administration
of drug therapies, inhaled medicine is increasingly being viewed as
patient-friendly and cost-effective. Our analysis indicated that
inhaled CNS administration is well positioned to take advantage of
these trends and evolve into a significant factor in the future of
pharmaceutical development and commercialization of CNS therapeutic
drugs.
These findings are examined in a new
and comprehensive survey written and researched by Greystone
Associates. The report includes detailed analysis of approved and
development-stage products, market sector participants and
technology and formulation factors.
Source: Greystone Associates
 |